Loading…
Atea Pharmaceuticals, Inc. is projected to rise to $6.07 by 2027, a +34% move from its current price of $4.55. AVIR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.44 | $4.55 | $4.67 | +0.04% |
| May 30 | $4.39 | $4.55 | $4.72 | +0.08% |
| May 31 | $4.36 | $4.56 | $4.76 | +0.12% |
| Jun 1 | $4.33 | $4.56 | $4.80 | +0.16% |
| Jun 2 | $4.31 | $4.56 | $4.83 | +0.20% |
| Jun 3 | $4.28 | $4.56 | $4.86 | +0.24% |
| Jun 4 | $4.26 | $4.56 | $4.88 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.26 | $4.56 | $4.88 | +0.28% |
| Week 2 | $4.16 | $4.58 | $5.03 | +0.55% |
| Week 3 | $4.08 | $4.59 | $5.16 | +0.83% |
| Week 4 | $4.02 | $4.60 | $5.27 | +1.11% |
| Week 5 | $3.97 | $4.61 | $5.37 | +1.38% |
| Week 6 | $3.92 | $4.63 | $5.46 | +1.66% |
| Week 7 | $3.88 | $4.64 | $5.55 | +1.94% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Atea Pharmaceuticals, Inc. is a healthcare company that operates as a clinical-stage biopharmaceutical company, discovering, developing, and commercializing oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
The company is also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection, and it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Atea Pharmaceuticals, Inc. (AVIR) operates in the Healthcare sector and is currently trading as a stock with a current price of $4.42 and a market capitalization of $353.72M. The company holds the 3352nd rank by market capitalization in its universe.
The forecast trajectory shows year-by-year price expectations, with the average price rising from $4.42 in 2026 to $8.70 in 2030 and further to $55.51 by 2050, while max values reach $12.65 in 2030, $49.49 in 2040, and $101.93 in 2050. Overall, the outlook trends bullish across the forecast years, with corresponding ROI figures climbing from 0% in 2026 to well into the hundreds of percent by 2050.
A major floor 32.7% below — a decisive break under it would weaken the trend.
The nearest floor, 9.9% below — buyers have tended to step in here.
The nearest ceiling, 29.2% above — a clean break opens room to run.
A major ceiling 45.6% above — clearing it would confirm fresh momentum.
Key AVIR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AVIR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.39 | Buy | $4.45 | Buy |
| MA 10 | $4.32 | Buy | $4.52 | Buy |
| MA 20 | $4.93 | Sell | $4.79 | Sell |
| MA 50 | $5.35 | Sell | $5.04 | Sell |
| MA 100 | $4.87 | Sell | $4.82 | Sell |
| MA 200 | $4.04 | Buy | $4.35 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.23 | Neutral |
| Stoch RSI (14) | 62.67 | Neutral |
| CCI (20) | -41.07 | Neutral |
| Williams %R (14) | -68.75 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -16.21 | Sell |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 31.25 | Neutral |
| TRIX (15) | -0.79 | Sell |
| Awesome (5,34) | -0.84 | Sell |
| Ultimate (7,14,28) | 69.06 | Neutral |
| Momentum (10) | -0.95 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 4.53 | Buy |
| ADX (14) | 25.48 | Sell |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is described as BULLISH. The RSI(14) is 30, with the 50-day simple moving average at $5.42 and the 200-day simple moving average at $4.03. Support is listed at $4.10 and resistance at $5.88, framing a thirty-day price range from a low of $3.71 to a high of $5.27.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.40 | $4.55 | $6.10 | 0% | Neutral | |
| $4.85 | $6.07 | $8.05 | +34% | Bullish | |
| $5.01 | $6.44 | $8.82 | +41% | Bullish | |
| $5.64 | $7.40 | $10.42 | +63% | Bullish | |
| $6.96 | $9.31 | $13.40 | +105% | Bullish | |
| $8.42 | $11.45 | $16.81 | +152% | Bullish | |
| $10.12 | $13.99 | $20.91 | +207% | Bullish | |
| $10.89 | $15.27 | $23.20 | +236% | Bullish | |
| $11.46 | $16.30 | $25.14 | +258% | Bullish | |
| $12.70 | $18.32 | $28.65 | +303% | Bullish | |
| $21.43 | $32.86 | $54.48 | +622% | Bullish | |
| $36.73 | $62.56 | $113.01 | +12.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.40 | $4.55 | $5.37 | +0.00% |
| June 2026 | $4.04 | $4.74 | $5.69 | +4.20% |
| July 2026 | $3.99 | $4.72 | $5.73 | -0.53% |
| August 2026 | $3.91 | $4.65 | $5.70 | -1.45% |
| September 2026 | $3.98 | $4.75 | $5.88 | +2.24% |
| October 2026 | $4.02 | $4.83 | $6.02 | +1.66% |
| November 2026 | $3.95 | $4.77 | $5.98 | -1.28% |
| December 2026 | $3.99 | $4.84 | $6.10 | +1.40% |
Click any year to see its month-by-month AVIR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect AVIR to range from $3.40 to $6.10 through 2026. The $4.55 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The AVIR price prediction for 2027 points to an average of $6.07 (low $4.85, high $8.05) — a potential gain of +34% on today's $4.55. Momentum favours further upside here.
In 2028, AVIR is projected to trade between $5.01 and $8.82, averaging $6.44 — a potential gain of +41% from today's $4.55. That is up +6% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Atea Pharmaceuticals, Inc.'s 2029 outlook centres on $7.40, within a $5.64 to $10.42 range. That is up +15% on the projected 2028 average. That marks a +63% change versus current levels. Momentum favours further upside here.
By 2030, AVIR could reach as high as $13.40, with a base case around $9.31 and support toward $6.96 — roughly +105% from $4.55. Buyers look set to stay in control over this stretch.
Expect AVIR to range from $8.42 to $16.81 through 2031. The $11.45 average target implies a +152% move from current prices. That is up +23% on the projected 2030 average. Momentum favours further upside here.
The AVIR price prediction for 2032 points to an average of $13.99 (low $10.12, high $20.91) — a potential gain of +207% on today's $4.55. Buyers look set to stay in control over this stretch.
In 2033, AVIR is projected to trade between $10.89 and $23.20, averaging $15.27 — a potential gain of +236% from today's $4.55. That is up +9% on the projected 2032 average. Momentum favours further upside here.
Atea Pharmaceuticals, Inc.'s 2034 outlook centres on $16.30, within a $11.46 to $25.14 range. That is up +7% on the projected 2033 average. That marks a +258% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, AVIR could reach as high as $28.65, with a base case around $18.32 and support toward $12.70 — roughly +303% from $4.55. Momentum favours further upside here.
Expect AVIR to range from $21.43 to $54.48 through 2040. The $32.86 average target implies a +622% move from current prices. That is up +79% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The AVIR price prediction for 2050 points to an average of $62.56 (low $36.73, high $113.01) — a potential gain of +12.7x on today's $4.55. Momentum favours further upside here.
Investing $1,000 in AVIR today (≈ 219.78022 AVIR) could be worth
$13,749.56
+$12,749.56 (+1275%) by 2050 · US Dollar
Based on the average projected AVIR price of $62.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AVIRwould be worth at today's price.
$1,000 invested in AVIR on May 27, 2025 (≈ 338.983045 AVIR) would be worth
$1,542.37
+$542.37 (+54.2%) today · 1.54× · US Dollar
Based on a AVIR entry price of $2.95 vs. today's $4.55.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.19 | $1,085.92 | +8.6% |
| 1 month ago | $5.36 | $848.88 | -15.1% |
| 3 months ago | $4.68 | $972.22 | -2.8% |
| 6 months ago | $3.1 | $1,467.74 | +46.8% |
| 1 year ago | $2.95 | $1,542.37 | +54.2% |
| All time (5.0y) ago | $20.51 | $221.84 | -77.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AVIR forecast.
Our base-case forecast reaches $9.10 around 2030.
Implied market cap at $9.10: $728.25M
The multi-year outlook shows a continuing bullish tilt, with the average price rising across key years: $4.42 (2026), $5.83 (2027), $6.05 (2028), $6.96 (2029), $8.70 (2030), $10.59 (2031), $13.00 (2032), $14.09 (2033), $14.87 (2034), $16.79 (2035), $29.44 (2040), and $55.51 (2050). The corresponding ROI figures expand from 0% in 2026 to 31.9% (2027), 36.9% (2028), 57.4% (2029), 96.9% (2030), 139.5% (2031), 194.2% (2032), 218.8% (2033), 236.3% (2034), 279.9% (2035), 566% (2040), and 1,155.8% (2050). The sentiment in the forecast shifts to BULLISH from 2027 onward.
These are estimates and not guarantees, reflecting the forecasted path of prices and returns on AVIR across the coming years.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $8.70, with a min of $6.46 and a max of $12.65, and an estimated ROI of 96.9%. The sentiment is BULLISH for 2030.
Forecasts indicate a bullish sentiment from 2027 onward, with the average price rising to $8.70 by 2030 and higher by 2040 and 2050. ROI is projected to be 31.9% in 2027, climbing to 1,155.8% by 2050, though these are estimates, not guarantees.
Yes. The forecast shows a max price of $101.93 in 2050, which would exceed $100.
Current price is $4.42 and market cap is $353.72M.
The thirty-day range is from a low of $3.71 to a high of $5.27.
Atea Pharmaceuticals, Inc. Community Discussion
0Share your Atea Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.